Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Rhea-AI Summary
Adia Med (OTCQB: ADIA) reported second-quarter 2026 revenue of approximately $485,000, up about 175% sequentially from $176,275 in Q1 2026, and achieved its first quarterly net income of roughly $40,000. First-half 2026 revenue reached $661,660, almost matching the company’s full-year 2025 revenue of about $700,508.
According to Adia Med, growth was supported by higher patient volume for regenerative treatments, expanded commercialization of Adia Labs biologic products such as AdiaVita™, and operational efficiencies that improved gross margins. The company completed Phase 1 and began Phase 2 of its Autism Spectrum Disorder study and is advancing additional Chronic Kidney Disease and orthopedic studies.
Positive
- Q2 2026 revenue ~$485,000, about 175% sequential growth from $176,275 in Q1 2026
- First-half 2026 revenue $661,660, nearly equal to full-year 2025 revenue of about $700,508
- First quarterly net income of approximately $40,000 in Q2 2026
- Higher gross profit margins from increased mix of high-margin biologic products and procedures
- Expansion of Adia Labs biologics sales, including AdiaVita™ and related products
- Clinical pipeline advancement with Phase 1 completed and Phase 2 launched in ASD study
Negative
- None.
News Market Reaction – ADIA
In the Aug 13 session, ADIA gained 0.42%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
Inline Viewer: ADIA NUTRITION, INC. 10-Q 2026-06-30
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg
Second Quarter 2026 Highlights
2026 revenue of
$661,660 is already ~94-95% of the company's full-year 2025 revenue of ~$700,508 . That is a very strong growth signal and one of the cleanest ways to show the business is accelerating.Total revenue of approximately
$485,000 , representing sequential growth of approximately175% from$176,275 in the first quarter of 2026 and a substantial increase over prior-year levels.Net income of approximately
$40,000 , marking the Company's first profitable quarter.Continued expansion of high-margin biologics sales through Adia Labs and growth in medical procedure volume at Adia Med clinics.
Ongoing progress in Institutional Review Board (IRB)-approved clinical studies, including the Autism Spectrum Disorder (ASD) study, Chronic Kidney Disease (CKD) study, and other regenerative therapy programs.
"We're seeing real progress as we grow our regenerative medicine business," said Larry Powalisz, Chief Executive Officer of Adia Med. "Reaching nearly half a million dollars in revenue this quarter and turning our first profit shows that more people want our stem cell treatments, biologics, and clinical services. The numbers are moving in the right direction, and we're making solid headway on our research programs at the same time. This puts us in a better place as we keep building the company for the long run and look at possible uplisting options."
The strong second-quarter performance was driven by increased patient volume for regenerative treatments, expanded commercialization of Adia Labs products (including AdiaVita™ and related biologics), and operational efficiencies across the Company's clinic and laboratory operations. Gross profit margins improved with a higher contribution from higher-margin biologic product sales and procedures.
Adia Med continues to advance its clinical research initiatives. The Company recently completed Phase 1 and launched Phase 2 of its ASD clinical study and is progressing additional studies in areas such as chronic kidney disease and orthopedic conditions. These programs support both clinical validation and future commercial opportunities.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
(OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309500